Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin

Raymond Bergan, Edward Kyle, Phuongmai Nguyen, Jane Trepel, Christian Ingui, Len Neckers

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The isoflavinoid genistein is a protein-tyrosine kinase inhibitor which has been identified as a putative cancer prevention agent. Its consumption is associated with a low incidence of clinical metastatic prostate cancer in the face of a sustained high incidence of organ-confined prostate cancer. We therefore undertook studies to examine genistein's effect upon cell adhesion as one possible mechanism by which it could be acting as an antimetastatic agent. A morphogenic analysis revealed that genistein caused cell flattening in a variety of cell lines: PC3-M, PC3, and DU-145 prostate carcinoma cells, as well as MCF-7 breast carcinoma cells. Mechanistic studies focused on the highly metastatic PC3-M cell line, and revealed that cell flattening was accompanied by an increase in cell adhesion. Further investigations demonstrated that focal adhesion kinase (FAK) accumulated in areas of focal cell attachment, and that this accumulation occurred only when cells were actively undergoing genistein-mediated morphologic change. Concurrent formation of a complex between the cell attachment molecule, beta-1-integrin, and FAK was shown to occur, and to correlate with transient activation of FAK activity. Genistein is presented as a novel investigative tool for use in the study of molecular events involved in the process of cell adhesion.

Original languageEnglish (US)
Pages (from-to)389-398
Number of pages10
JournalClinical and Experimental Metastasis
Volume14
Issue number4
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Integrin beta Chains
Focal Adhesion Protein-Tyrosine Kinases
Genistein
Prostatic Neoplasms
Cell Adhesion
Focal Adhesion Kinase 1
Cell Line
Incidence
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Prostate
Breast Neoplasms
Carcinoma

Keywords

  • Adhesion
  • Focal adhesion kinase
  • Genistein
  • Integrin
  • Prostate

ASJC Scopus subject areas

  • Cancer Research

Cite this

Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. / Bergan, Raymond; Kyle, Edward; Nguyen, Phuongmai; Trepel, Jane; Ingui, Christian; Neckers, Len.

In: Clinical and Experimental Metastasis, Vol. 14, No. 4, 1996, p. 389-398.

Research output: Contribution to journalArticle

Bergan, Raymond ; Kyle, Edward ; Nguyen, Phuongmai ; Trepel, Jane ; Ingui, Christian ; Neckers, Len. / Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. In: Clinical and Experimental Metastasis. 1996 ; Vol. 14, No. 4. pp. 389-398.
@article{b0ce2486133d46cc8769fe02f5b4b6eb,
title = "Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin",
abstract = "The isoflavinoid genistein is a protein-tyrosine kinase inhibitor which has been identified as a putative cancer prevention agent. Its consumption is associated with a low incidence of clinical metastatic prostate cancer in the face of a sustained high incidence of organ-confined prostate cancer. We therefore undertook studies to examine genistein's effect upon cell adhesion as one possible mechanism by which it could be acting as an antimetastatic agent. A morphogenic analysis revealed that genistein caused cell flattening in a variety of cell lines: PC3-M, PC3, and DU-145 prostate carcinoma cells, as well as MCF-7 breast carcinoma cells. Mechanistic studies focused on the highly metastatic PC3-M cell line, and revealed that cell flattening was accompanied by an increase in cell adhesion. Further investigations demonstrated that focal adhesion kinase (FAK) accumulated in areas of focal cell attachment, and that this accumulation occurred only when cells were actively undergoing genistein-mediated morphologic change. Concurrent formation of a complex between the cell attachment molecule, beta-1-integrin, and FAK was shown to occur, and to correlate with transient activation of FAK activity. Genistein is presented as a novel investigative tool for use in the study of molecular events involved in the process of cell adhesion.",
keywords = "Adhesion, Focal adhesion kinase, Genistein, Integrin, Prostate",
author = "Raymond Bergan and Edward Kyle and Phuongmai Nguyen and Jane Trepel and Christian Ingui and Len Neckers",
year = "1996",
doi = "10.1007/BF00123398",
language = "English (US)",
volume = "14",
pages = "389--398",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin

AU - Bergan, Raymond

AU - Kyle, Edward

AU - Nguyen, Phuongmai

AU - Trepel, Jane

AU - Ingui, Christian

AU - Neckers, Len

PY - 1996

Y1 - 1996

N2 - The isoflavinoid genistein is a protein-tyrosine kinase inhibitor which has been identified as a putative cancer prevention agent. Its consumption is associated with a low incidence of clinical metastatic prostate cancer in the face of a sustained high incidence of organ-confined prostate cancer. We therefore undertook studies to examine genistein's effect upon cell adhesion as one possible mechanism by which it could be acting as an antimetastatic agent. A morphogenic analysis revealed that genistein caused cell flattening in a variety of cell lines: PC3-M, PC3, and DU-145 prostate carcinoma cells, as well as MCF-7 breast carcinoma cells. Mechanistic studies focused on the highly metastatic PC3-M cell line, and revealed that cell flattening was accompanied by an increase in cell adhesion. Further investigations demonstrated that focal adhesion kinase (FAK) accumulated in areas of focal cell attachment, and that this accumulation occurred only when cells were actively undergoing genistein-mediated morphologic change. Concurrent formation of a complex between the cell attachment molecule, beta-1-integrin, and FAK was shown to occur, and to correlate with transient activation of FAK activity. Genistein is presented as a novel investigative tool for use in the study of molecular events involved in the process of cell adhesion.

AB - The isoflavinoid genistein is a protein-tyrosine kinase inhibitor which has been identified as a putative cancer prevention agent. Its consumption is associated with a low incidence of clinical metastatic prostate cancer in the face of a sustained high incidence of organ-confined prostate cancer. We therefore undertook studies to examine genistein's effect upon cell adhesion as one possible mechanism by which it could be acting as an antimetastatic agent. A morphogenic analysis revealed that genistein caused cell flattening in a variety of cell lines: PC3-M, PC3, and DU-145 prostate carcinoma cells, as well as MCF-7 breast carcinoma cells. Mechanistic studies focused on the highly metastatic PC3-M cell line, and revealed that cell flattening was accompanied by an increase in cell adhesion. Further investigations demonstrated that focal adhesion kinase (FAK) accumulated in areas of focal cell attachment, and that this accumulation occurred only when cells were actively undergoing genistein-mediated morphologic change. Concurrent formation of a complex between the cell attachment molecule, beta-1-integrin, and FAK was shown to occur, and to correlate with transient activation of FAK activity. Genistein is presented as a novel investigative tool for use in the study of molecular events involved in the process of cell adhesion.

KW - Adhesion

KW - Focal adhesion kinase

KW - Genistein

KW - Integrin

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=0029961485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029961485&partnerID=8YFLogxK

U2 - 10.1007/BF00123398

DO - 10.1007/BF00123398

M3 - Article

VL - 14

SP - 389

EP - 398

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 4

ER -